Ascendis Pharma A/S
NASDAQ: ASND0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan Moller Mikkelsen
- Employees
- 1,017
- Headquarters
- Hellerup, Denmark
- IPO year
- 2015
- Market cap
- $14.3B
- Website
- https://ascendispharma.com
Loading ASND…
Loading profile data…Frequently asked questions about ASND
What does Ascendis Pharma A/S (ASND) do?
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline...
Where does ASND trade?
Ascendis Pharma A/S (ASND) trades on the NASDAQ Global Select.
What sector is ASND in?
Ascendis Pharma A/S (ASND) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ascendis Pharma A/S?
Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S (ASND).
Where is Ascendis Pharma A/S headquartered?
Ascendis Pharma A/S is headquartered in Denmark.
Does ASND pay a dividend?
Ascendis Pharma A/S (ASND) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ASND go public?
Ascendis Pharma A/S (ASND) completed its initial public offering in 2015.
Is ASND an ADR?
Yes — ASND is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Ascendis Pharma A/S reporting and dividends follow the underlying issuer.